Cargando…

The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is the 4(th )leading cause of mortality worldwide. Long-acting bronchodilators are considered first line therapies for patients with COPD but their effects on mortality are not well known. We performed a comprehensive systematic review and met...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kliber, Agnes, Lynd, Larry D, Sin, Don D
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876086/ https://www.ncbi.nlm.nih.gov/pubmed/20459831 http://dx.doi.org/10.1186/1465-9921-11-56

Ejemplares similares

Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease
por: Donohue, James F, et al.
Publicado: (2011)

Benefit–harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease
por: Ahmadian, Safa, et al.
Publicado: (2022)

Comparison of efficacy of long-acting bronchodilators in emphysema dominant and emphysema nondominant chronic obstructive pulmonary disease
por: Fujimoto, Keisaku, et al.
Publicado: (2011)

Prescribing Patterns for Long-Acting Inhaled Bronchodilators Among Rural Adults With Chronic Obstructive Pulmonary Disease
por: Brunner, Wendy M., et al.
Publicado: (2022)

Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease
por: Roberts, Melissa H., et al.
Publicado: (2019)

The paradoxical response to short-acting bronchodilator administration in patients with chronic obstructive pulmonary disease
por: Shin, Hong-Joon, et al.
Publicado: (2021)

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD
por: Kang, Jieun, et al.
Publicado: (2017)

Long-acting Inhaled Bronchodilator and Risk of Vascular Events in Patients With Chronic Obstructive Pulmonary Disease in Taiwan Population
por: Tsai, Ming-Jun, et al.
Publicado: (2015)

Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy
por: Bengtson, Lindsay G.S., et al.
Publicado: (2018)

Risk of adverse cardiovascular events with use of inhaled long-acting bronchodilators in management of chronic obstructive pulmonary disease
por: Wang, Meng-Ting, et al.
Publicado: (2019)

Long-acting Inhaled Bronchodilator and Risk of Vascular Events in Patients With Chronic Obstructive Pulmonary Disease in Taiwan Population: Erratum
Publicado: (2016)

Trends in hospital admissions for chronic obstructive pulmonary disease over 16 years in Canada
por: Amegadzie, Joseph E., et al.
Publicado: (2023)

Study on the Management of the Health Status of Patients with Stable Chronic Obstructive Pulmonary Disease Treated with Double Bronchodilator
por: Wang, Wei, et al.
Publicado: (2022)

Short-acting bronchodilators for the management of acute exacerbations of chronic obstructive pulmonary disease in the hospital setting: systematic review
por: Kopsaftis, Zoe A., et al.
Publicado: (2018)

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2013)

The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease
por: Beeh, Kai M.
Publicado: (2016)

Retracted: Study on the Management of the Health Status of Patients with Stable Chronic Obstructive Pulmonary Disease Treated with Double Bronchodilator
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids
por: Asche, Carl Victor, et al.
Publicado: (2012)

Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis
por: Naya, Ian, et al.
Publicado: (2019)

V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results
por: Devillier, Philippe, et al.
Publicado: (2015)

Risk of Pneumonia with Inhaled Corticosteroid versus Long-Acting Bronchodilator Regimens in Chronic Obstructive Pulmonary Disease: A New-User Cohort Study
por: DiSantostefano, Rachael L., et al.
Publicado: (2014)

Erratum: Triple Therapy versus Dual or Monotherapy with Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis
Publicado: (2021)

Bronchodilation improves endurance but not muscular efficiency in chronic obstructive pulmonary disease
por: van der Vaart, Hester, et al.
Publicado: (2011)

Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

The safety of long-acting β(2)-agonists in the treatment of stable chronic obstructive pulmonary disease
por: Decramer, Marc L, et al.
Publicado: (2013)

Characteristics of Patients with Chronic Obstructive Pulmonary Disease Treated with Long-Acting Bronchodilators in a Real-World Setting in Singapore: A Single-Center Observational Study
por: Sim, Marcus, et al.
Publicado: (2022)

Stable Clinical Course of Chronic Obstructive Pulmonary Disease Patients in the Era of Double Bronchodilator Therapy: A Single Referral Center Experience
por: Shin, Sun Hye, et al.
Publicado: (2020)

Total Antioxidant Status in Stable Chronic Obstructive Pulmonary Disease
por: Hlavati, Marina, et al.
Publicado: (2020)

Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?
por: Price, David, et al.
Publicado: (2014)

Severity Staging of Chronic Obstructive Pulmonary Disease: Differences in Pre- and Post-Bronchodilator Spirometry
por: Lin, Sheng-Hsiang, et al.
Publicado: (2009)

The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease
por: Halpin, David M. G.
Publicado: (2018)

Major comorbidities lead to the risk of adverse cardiovascular events in chronic obstructive pulmonary disease patients using inhaled long-acting bronchodilators: a case-control study
por: Chen, Yen-Fu, et al.
Publicado: (2019)

Long acting β(2 )agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials
por: Husereau, Don, et al.
Publicado: (2004)

Risk of cardiovascular events after initiation of long-acting bronchodilators in patients with chronic obstructive lung disease: A population-based study
por: Aljaafareh, Almotasembellah, et al.
Publicado: (2016)

Treatment of mild chronic obstructive pulmonary disease
por: Chee, Alex, et al.
Publicado: (2008)

Long-Acting Bronchodilator Use in Chronic Obstructive Pulmonary Disease in Primary Care in New Zealand: A Retrospective Study of Treatment Patterns and Evolution Using the HealthStat Database
por: Milea, Dominique, et al.
Publicado: (2021)

Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease
por: Pisi, Roberta, et al.
Publicado: (2015)

Role of the Bronchodilator Test Defined by the Forced Vital Capacity in Chronic Obstructive Pulmonary Disease Phenotyping
por: Zhang, Xiaoling, et al.
Publicado: (2020)

Comparison of Effectiveness Using Different Dual Bronchodilator Agents in Chronic Obstructive Pulmonary Disease Treatment
por: Cheng, Shih-Lung
Publicado: (2021)

Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis
por: Gan, Wen Qi, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_5tepusvct2e20cj7qs8asodhe9